|By PR Newswire||
|August 7, 2014 11:00 AM EDT||
NUSSLOCH, Germany, August 7, 2014 /PRNewswire/ --
- Leica Biosystems announces a collaboration with Bristol-Myers Squibb to develop companion diagnostic tests in support of targeted therapeutics
- Leica Biosystems will develop fully automated tissue-based companion diagnostic tests to run on the BOND™ automated advanced staining systems
Leica Biosystems, today announced an agreement with Bristol-Myers Squibb Company (NYSE: BMY) to collaborate on developing companion diagnostics on the Leica BOND system for use as an aid in selecting patients for treatment with certain pharmaceuticals developed, or to be developed, by Bristol-Myers Squibb. Other terms of the agreement were not disclosed.
"We are pleased to be working with Bristol-Myers Squibb, on diagnostics for cancer and other therapies on the Leica BOND platform," added Matthias Weber, President of Leica Biosystems, MD. "This partnership is an example of Leica's continued growth in Companion Diagnostics. In this field the capabilities to supply high quality In Vitro Diagnostic products are critical requirements. The ease of use and high staining quality of our BOND systems makes them ideal platforms on which to deploy these very informative tests."
About Leica Biosystems
Leica Biosystems is a global leader in workflow solutions and automation, striving to advance cancer diagnostics to improve patients' lives. Leica Biosystems provides anatomic pathology laboratories and researchers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. Leica's easy-to-use and reliable offerings help improve workflow efficiency and diagnostic confidence. The company is represented in over 100 countries. It has manufacturing facilities in seven countries, sales and service organizations in 19 countries, and an international network of dealers. The company is headquartered in Nussloch, Germany. Further information can be found at LeicaBiosystems.com.
May. 3, 2015 08:15 AM EDT Reads: 2,953
May. 3, 2015 08:00 AM EDT Reads: 1,694
May. 3, 2015 08:00 AM EDT Reads: 1,612
May. 3, 2015 07:45 AM EDT Reads: 872
May. 3, 2015 07:00 AM EDT Reads: 654
May. 3, 2015 06:00 AM EDT Reads: 4,643
May. 3, 2015 05:00 AM EDT Reads: 5,635
May. 3, 2015 02:45 AM EDT Reads: 5,692
May. 3, 2015 02:00 AM EDT Reads: 2,366
May. 3, 2015 12:00 AM EDT Reads: 1,847
May. 2, 2015 09:15 PM EDT Reads: 1,826
May. 2, 2015 06:00 PM EDT Reads: 2,346
May. 2, 2015 04:00 PM EDT Reads: 2,212
May. 2, 2015 04:00 PM EDT Reads: 2,411
Docker is becoming very popular--we are seeing every major private and public cloud vendor racing to adopt it. It promises portability and interoperability, and is quickly becoming the currency of the Cloud. In his session at DevOps Summit, Bart Copeland, CEO of ActiveState, discussed why Docker is so important to the future of the cloud, but will also take a step back and show that Docker is actually only one piece of the puzzle. Copeland will outline the bigger picture of where Docker fits a...
May. 2, 2015 02:15 PM EDT Reads: 5,067